F094 Melanoma in Situ: Ongoing Controversies and New Insights
DESCRIPTION
The primary clinical significance of melanocytic neoplasms lies in preventing deaths from melanoma through early detection, known as 'secondary prevention'. Achieving secondary prevention of melanoma requires distinguishing benign lesions from lesions likely to progress to metastatic disease without intervention and, b. identifying the latter lesions early enough to prevent progression. In this session, we delve into several challenging and contentious topics related to identifying and managing borderline melanocytic neoplasms with a focus on melanoma in situ. We will explore: a. the clinical and pathological challenges in classifying MIS, b. the risks and benefits of intensifying detection efforts for MIS, and c. the roles of emerging technologies, including AI and molecular profiling, in aiding detection and classification.
LEARNING OBJECTIVES
Discuss the significance of melanoma in situ
Discuss the challenges and opportunities in classifying MIS and applying AI to melanoma diagnosis
Discuss the changing landscape of melanoma education and screening
SCHEDULE
3:30 PM
Introduction: Is Melanoma In Situ 'Cancer'
Allan C. Halpern, MD, FAAD
3:50 PM
MIS and Public Health: Implications for Screening and Education
Collin Costello, MD, FAAD
4:10 PM
Molecular Profiling of MIS: Boon or Bane for Melanoma Diagnosis
Shirin Bajaj, MD, FAAD
4:30 PM
Balancing Act: Integrating MIS with Borderline Lesions in MPath
Ata Moshiri, MD, MPH, FAAD
4:50 PM
AI Training and Application at the MIS Boundary
Laura K. Ferris, MD, PhD, FAAD
5:10 PM
Panel Discussion
DIRECTOR
Allan C. Halpern, MD, FAAD
SPEAKERS
Shirin Bajaj, MD, FAAD
Collin Costello, MD, FAAD
Laura K. Ferris, MD, PhD, FAAD
Ata Moshiri, MD, MPH, FAAD
DISCLOSURES
Shirin Bajaj, MD, FAAD
No financial relationships exist with ineligible companies.
Collin Costello, MD, FAAD
DeepX Health – Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Melanoma Research Alliance – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding);
Laura K. Ferris, MD, PhD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Other Financial Benefit); Almirall – Consultant (1099 relationship)(Honoraria); Amgen – Investigator(Other Financial Benefit); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Other Financial Benefit), Speaker(Honoraria); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Consultant(Honoraria); Castle Biosciences, Inc – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Consultant(Honoraria); Janssen Research & Development, LLC – Investigator(Other Financial Benefit); Novartis – Investigator(Other Financial Benefit); Pfizer Inc. – Data Safety Monitoring Board(Honoraria); Regeneron – Consultant(Honoraria), Investigator(Other Financial Benefit); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); UCB – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Investigator(Grants/Research Funding);
Allan C. Halpern, MD, FAAD
Canfield Scientific, Inc. – Consultant(Other Financial Benefit); SpotDoc – Founder(Other Financial Benefit);
Ata Moshiri, MD, MPH, FAAD
No financial relationships exist with ineligible companies.